Latest Headlines

Latest Headlines

Sanofi and Innate Pharma team up on anticancer ADCs

Sanofi has reached out to its French neighbor Innate Pharma to collaborate on armed antibody treatments, borrowing the biotech's technology to craft new treatments for cancer and inflammatory disease.

Japan's Senju licenses Eyenovia ophthalmic therapy for sale Asia-wide

Japan's Senju Pharmaceutical has licensed U.S.-based Eyenovia's portfolio of microdosed ophthalmic treatments to develop and market throughout Asia. Financial arrangements were not disclosed, but the global market for such drugs is $19 billion.

Japan's CiRA, Takeda in clinical pact on stem cell R&D led by Nobel laureate Yamanaka

The Center for iPS Cell Research Application (CiRA) of Kyoto University and Takeda Pharmaceutical Company announced a decade-long R&D effort to discover new applications for induced pluripotent stem cells in areas such as heart failure, diabetes mellitus, neurological disorders and cancer immunotherapy, according to a press release.

Samsung partners to develop next-gen health and wellness software, mobile apps

Samsung, along with several other electronics conglomerates, is working to puzzle out what's next in mobile healthcare. A growing foothold in healthcare could aid these companies, which are vulnerable to the vagaries of eroding profit margins and rapidly evolving technology.

Recipharm bets on a U.S. biotech with an R&D joint venture

Swedish contract drug developer Recipharm has signed a deal with Virginia's Synthonics, investing in the biotech and lending its expertise in the development of new compounds.

Two ophthalmology CROs join forces for ocular R&D

Iris Pharma and Oculos Clinical Research, two CROs focused on the eye, have inked a strategic alliance to boost their profiles in the contracting world.

Aptuit pairs up with an Italian CRO for drug discovery

U.S. contractor Aptuit has signed a deal with Italy's Axxam to team up on early-stage R&D services, pooling their resources to better compete for projects.

Quick China dealmaking as TVM, Lummy tie with Argos on oncology candidate

TVM Capital Life Science moved quickly to tap a new $50 million venture capital fund with investment from Chinese partner Lummy Co. in a licensing deal for an oncology dendritic vaccine.

Alibaba's latest move in China online drug sales is $2.51B shift of Tmall

Alibaba Group Holding aims to ramp up fledgling online drug sales in China by placing online drug retailer Tmall under its listed healthcare unit in a shuffle estimated at $2.51 billion, the company said in a press release.

Taxus Cardium Generx drug development gets amped up investment

A promising angiogenic gene therapy candidate in development for nearly two decades has drawn in further investment from China-based Shenzhen Qianhai Taxus Industry Capital Management, picking up a 15% stake in Angionetics, a newly formed subsidiary of Taxus Cardium Pharmaceuticals Group.